ABT-546 (A-216546) is a potent, highly selective, and active endothelin ETA receptor antagonist; it blocks endothelin-1-induced vasoconstriction mediated by ETA receptors and inhibits endothelin-1-induced pressor responses in vivo in a dose-dependent manner; it also inhibits endothelin-1-induced arachidonic acid release and phosphatidylinositol hydrolysis with IC50 values of 0.59 nM and 3 nM, respectively.